Scholar Rock (SRRK) Q4 2025 earnings review
Regulatory Fog Lifting as Balance Sheet Gets a Massive $550M Backstop
Scholar Rock remains a pre-revenue biotech entirely consumed by the regulatory delay of its lead asset, apitegromab. The Q4 release brings two crucial pieces of de-risking news: first, the FDA held a constructive meeting with Novo Nordisk's Catalent facility (the sole reason for the September 2025 Complete Response Letter) and requested no new corrective actions. Second, management secured a $550M debt facility from Blue Owl Capital, essentially eliminating near-term financing overhangs as they wait out the regulatory clock. Net loss for the quarter was $91.0M, driven heavily by General and Administrative (G&A) expenses (+137% YoY) as the company maintains its sidelined commercial team in anticipation of a 2026 U.S. launch.
🐂 Bull Case
The FDA's early Q1 2026 meeting with Catalent Indiana requested no additional corrective actions. This isolates the delay strictly to an unannounced reinspection, keeping the 2026 launch timeline highly viable without requiring new clinical trials.
The $550M Blue Owl debt facility provides massive, non-dilutive optionality. The company already ended Q4 with $367.6M in cash, and pulling down the next $100M tranche in 25Q1 ensures they can weather launch delays without punishing equity dilution.
🐻 Bear Case
Despite positive FDA interactions, the actual BLA resubmission hinges entirely on when the FDA decides to conduct an unannounced reinspection of Novo Nordisk's Catalent facility. Until that happens, the timeline remains in limbo.
G&A expenses hit $176.2M for the full year (up from $67.5M in FY24). Maintaining a fully hired, 50-person commercial team while waiting for regulatory clearance is burning significant cash that yields no immediate return.
⚖️ Verdict: 🟢
Bullish. For a pre-commercial biotech hit by a third-party manufacturing CRL, this is the best possible Q4 update. The FDA is satisfied with Catalent's remediation plan, and the Blue Owl debt facility removes the dreaded 'capital raise from a position of weakness' scenario.
Key Themes
Massive Balance Sheet De-Risking via Blue Owl Debt
Management directly addressed the market's biggest concern—cash burn during a regulatory delay—by securing up to $550M in debt from Blue Owl Capital maturing in 2032. They drew $100M at close to retire Oxford Finance debt, will draw another $100M in Q1 2026, and have $150M gated behind apitegromab approval. This significantly extends their cash runway, which was previously guided 'into 2027,' and protects current shareholders from dilutive equity raises during the Catalent wait.
Catalent Remediation is Tracking Positively
The apitegromab BLA resubmission was stalled by an Official Action Indicated (OAI) status at Novo Nordisk's Catalent Indiana facility. Q4 materials confirm a critical milestone: the FDA met with Catalent in early Q1 2026, reviewed remediation progress, and requested no new corrective actions. This accelerates confidence that an FDA reinspection will be successful, clearing the single gating item for BLA resubmission.
High Carrying Costs of Pre-Commercial Infrastructure
While management claims to be ready for a 2026 launch, keeping the engines idling is expensive. G&A expenses skyrocketed 137% YoY in Q4 to $45.0M. However, it's worth noting that Q4 G&A decelerated sequentially from Q3's $53.1M. This data point slightly contradicts the narrative of unchecked 'launch readiness'—it suggests management is quietly pulling back some spending to preserve cash until the FDA reinspection date is clearer.
Supply Chain Redundancy Advancing
Learning from the Catalent debacle, Scholar Rock is aggressively accelerating a second U.S.-based fill-finish facility. Engineering runs are already underway, with manufacturing runs planned through Q2 2026. The company plans to submit a supplemental BLA (sBLA) for this facility later in 2026, transitioning it from an 'insurance policy' to a core pillar of their commercial supply chain.
Subcutaneous Formulation (SRK-439) Pipeline Progression
The company is advancing a subcutaneous formulation, SRK-439, a novel myostatin inhibitor that binds selectively to pro- and latent myostatin without GDF11 or Activin A binding. With a Phase 1 study in healthy volunteers underway and topline data expected in H2 2026, this represents a crucial lifecycle management strategy to defend against future competition requiring more convenient administration.
Other KPIs
Accelerating slightly (+13% YoY) from $184.5 million in FY24. Interestingly, Q4 standalone R&D ($46.9M) actually decelerated YoY (down from $50.4M in 24Q4). This implies that peak clinical trial spending (like the SAPPHIRE trial) has passed, and R&D costs are transitioning heavily into commercial manufacturing and technology transfer for the second fill-finish site.
The company successfully brought in $60.4M in Q4 2025 from the exercise of outstanding warrants. This influx helped keep the sequential Q3-to-Q4 cash balance effectively flat ($369.6M to $367.6M) despite the $91M net loss for the quarter, showcasing strong opportunistic capital management.
Guidance
Stable expectation, but heavily conditional. Management continues to guide for a 2026 BLA resubmission and launch. This assumes the unannounced FDA reinspection of Catalent happens soon and results in a rapid approval.
Stable. The European Medicines Agency (EMA) decision is anticipated in mid-2026, with the launch expected in the second half of the year, starting with Germany. This acts as a potential revenue hedge if U.S. facility issues drag on, assuming the EMA does not cross-apply the FDA's Catalent observations.
Stable. The IND is cleared, and the company expects to initiate this randomized, double-blind trial for facioscapulohumeral muscular dystrophy (FSHD) in mid-2026, expanding the total addressable market for apitegromab beyond the 35,000 global SMA patients.
Key Questions
Catalent Reinspection Mechanics
Given that FDA reinspections are unannounced, what is the latest possible date the reinspection could occur to still allow for a Q4 2026 commercial launch, factoring in the time required for a Class 1 or Class 2 BLA resubmission review?
EMA Cross-Read Risk
The EMA decision is anticipated in mid-2026. If the FDA has not reinspected and cleared the Catalent facility by then, how will that impact the European Marketing Authorisation Application (MAA), given mutual reliance frameworks?
Second Facility Pivot
If the Catalent reinspection is delayed or fails, can the supplemental BLA (sBLA) for the second fill-finish facility, expected later in 2026, be upgraded to serve as the primary manufacturing facility for the initial BLA approval?
Pacing Commercial Spend
We noticed a sequential decline in Q4 G&A expenses compared to Q3. Have you implemented specific cost-containment measures on the commercial side while awaiting the Catalent resolution, and what is the expected quarterly G&A run-rate through mid-2026?